Abstract. It has been well established that raloxifene improves bone turnover, increases bone mineral density (BMD), and reduces the risk of fractures. However, it remains obscure which patients are more likely to respond to treatment with raloxifene in patients with postmenopausal osteoporosis. The purpose of this study was to investigate associations between baseline values of BMD and bone turnover markers (BTMs) and changes of those values after 1-year treatment with raloxifene. Sixty-eight Japanese postmenopausal women with untreated osteoporosis were selected for this study, among whom 58 patients (mean age 70.40 ± 9.2 years) completed this study. Lower baseline values of BMD at the lumbar spine, the femoral neck, and the distal radius were significantly correlated with greater increases of BMD at those corresponding sites after 1-year treatment with raloxifene. On the other hand, higher baseline values of bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx) were significantly correlated with greater reductions of BAP and NTx, respectively, after 1-year treatment with raloxifene. Although longer and larger studies with fracture endpoints are needed, our findings suggest that baseline values of BMD and BTMs can be used to predict subsequent skeletal response to raloxifene therapy in Japanese postmenopausal women with osteoporosis.
IT has been well established that raloxifene (RLX) improves accelerated bone turnover, increases bone mineral density (BMD) at the lumbar spine (LS) and at the femoral neck (FN), and reduces the risk of new vertebral fractures [1] [2] [3] . However, it seems relatively obscure which patients are more likely to respond to treatment with RLX in patients with postmenopausal osteoporosis.
Indeed, using the same population (the MORE study database) enrolling primarily Caucasians, some investigators have suggested that the efficacy of RLX on reducing fracture risk may be more prominent in patients with higher bone turnover [4] [5] [6] or lower BMD at baseline [4, 6, 7] . Although the ultimate aim of treatment for osteoporosis is surely the prevention of fractures, evaluation of its anti-fracture effects requires larger number of patients with longer durations of not less than several years [8] . Thus, at a clinical level, response to treatment for osteoporosis is indirectly estimated by measuring surrogate measures that may be more quickly and easily measured, such as BMD or bone turnover markers (BTMs), although some controversies exist as to whether those surrogate measures are reliable for predicting fracture efficacy [8] . However, thus far, no clinical trials of RLX have focused on which patients are more responsive to treatment with RLX in terms of BMD and BTMs.
On the other hand, numerous trials have vigorously examined which patients are more likely to respond to treatment with other antiresorptive agents. Some have shown that bisphosphonates increase BMD more in osteoporotic patients with lower baseline BMD [9] . Others have demonstrated that higher baseline values or greater on-therapy reductions of BTMs are associated with greater increases in bone mass [9] [10] [11] [12] [13] and greater reductions of vertebral and non-vertebral fractures [14, 15] among bisphosphonate-treated patients. A similar trend has been reported in patients treated with other antiresoptive agents including calcitonin [16] and hormone replacement therapy (HRT) [17, 18] . These observations suggest that antiresorptive agents may be more efficacious in patients with more evident osteoporosis or higher bone turnover, which is of great use in making clinical decision for those patients with osteoporosis because early identification of individuals who will not respond to treatment is the primary concern of clinical practice as Sarkar et al. [6, 7] and Kim et al. [13] argued in their reports.
Therefore, the purpose of our study was to reveal which patients are more likely to respond to treatment with RLX, by investigating associations between baseline values of BTMs and BMD and those values after treatment with RLX in Japanese postmenopausal women with osteoporosis.
Subjects and Methods

Subjects
Sixty-eight Japanese postmenopausal women (mean age 71.03 ± 9.1 years, from 52 to 91 years) with untreated osteoporosis, with their last menstrual period at least 2 years before, and without clinically significant postmenopausal symptoms, including hot flushing, at the beginning of this study, who initially attended the clinic of Rakuwakai Otowa Hospital between April 2004 and February 2006, were selected for this study. These subjects include a part of those in another recent study of ours [19] , and are a part of those in another one [20] . The diagnosis of osteoporosis was established on the basis of T-score of bone mineral density (BMD) at least 2.5 SDs below the young adult mean, and along with the criteria for the diagnosis of osteoporosis in Japan [21] . Osteoporosis in all patients began to be treated with RLX (60 mg/day). During the course of this study, the dose of RLX was unchanged. This study involved a 12-month (at baseline, 6 months and 12 months after the diagnosis) longitudinal examination of these 68 patients.
All subjects completed a questionnaire administered by the doctor or the nurse prior to entry into the study, and underwent laboratory blood and urinary tests. To avoid adverse reaction of RLX, we excluded subjects who had a history of deep venous thrombosis, and those who could not walk well by themselves. We also excluded smokers, those who had a history of other diseases (type 1 diabetes mellitus, liver disease, renal dysfunction, malignancy, hyperthyroidism, hyperparathyroidism, hypercorticoidism, or hypogonadism), and those taking medications (active vitamin D 3 , bisphosphonates, calcitonin, estrogens, testosterones, steroids, thyroid hormones, diuretics, heparin or anticonvulsants) that could influence bone metabolism. All the subjects underwent plain x-ray (antero-posterior and lateral views) of the LS, and those found to have scoliosis, compression fracture of the lumbar vertebrae among L2-L4, or ectopic calcifications that could interfere with the bone mineral results were excluded.
This study was performed in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethical Committee of Rakuwakai Otowa Hospital. All the patients gave their informed consent before they were enrolled.
BMD measurements
BMD was measured at 3 sites, including LS (L2-L4), FN, distal 1/3 radius (DR), by means of dual energy X-ray absorptiometry (DXA) (Hologic QDR 4500c; Hologic Inc. Waltham, MA, USA) at baseline, and 6 months and 12 months after the initiation of treatment. To eliminate technical discrepancies, the same operator measured all the subjects. The reproducibility was calculated as coefficient of variation obtained by daily measurements of a standard phantom over a period of 2 years. The CV of our instrument is 0.43% with the standard phantom. Values of BMD at the LS were expressed as the mean of those at the L2-L4. T-scores and Z-scores were calculated on the basis of the normal reference values of the age-and gender-matched Japanese group provided by the DXA system manufacturer.
Biochemical measurements
All subjects underwent laboratory blood tests at baseline, at the 6 months, and at the 12 months. Serum samples were obtained before 9:00 AM after an overnight fast, and were immediately processed and kept frozen at -20°C until the assays were carried out. Serum calcium (Ca) and phosphate (P) were measured with standard laboratory methods. Serum bone-specific alkaline phosphatase (BAP) was measured with an enzyme immunoassay kit (Osteolinks-BAP; Sumitomo Pharmaceuticals Inc., Tokyo, Japan; reference range: 9.6-35.4 U/L) as a marker of bone formation. Serum N-terminal telopeptide of type I collagen (NTx) was measured by means of an enzyme-linked immunosorbent assay (OSTEOMARK; Mochida Pharmaceutical Co., Tokyo, Japan; reference range: 7.5-16.5 nmolBCE/L for premenopausal women, and 10.7-24.0 nmolBCE/L for postmenopausal women) as a marker of bone resorption.
Statistical analysis
Data were analyzed by paired t-test for longitudinal differences, and by Pearson's correlation test for determining correlations. Statistics were calculated with StatView version 5.0 (Abacus Concepts, Inc., Berkeley, CA, USA). A P value <0.05 was considered statistically significant.
Results
Characteristics of the patients who discontinued this study and those who completed this study Of the 68 patients enrolled, 10 patietns discontinued this study. Among them, one patient reported muscle pain for the entire body, and one reported leg cramps. Both of these adverse events were resolved spontaneously with cessation of RLX. Other 3 patients discontinued due to changing their address. The other 5 patients discontinued because they could not adhere to the protocol of this study during the course. No case of venous thromboembolic event, clinical bone fracture, or other serious treatment-emergent events was reported. In the result, 58 patients (mean age 70.40 ± 9.2 years) completed this study. Table 1 shows their baseline and longitudinal characteristics.
Longitudinal changes in BMD and BTMs
BMD was significantly increased at the LS both at the 6 month and at the 12 month compared with at the baseline (p = 0.005, and p<0.001, respectively), but not at the FN or the DR ( Table 1 ). The percent change of BMD compared with the baseline was also significant only at the LS both at the 6 month (2.91 ± 7.3%, p = 0.004) and at the 12 month (4.91 ± 6.9%, p< 0.001), but not at the FN or the DR.
On the other hand, both BAP and NTx were significantly reduced by -8.81 ± 30.9% (p = 0.034) and -21.84 ± 24.0% (p<0.001), respectively, at the 6 month, and by -19.87 ± 32.5% (p<0.001), and -27.17 ± 19.5% (p<0.001), respectively, at the 12 month, compared with those at the baseline (Table 1) .
Correlation between baseline clinical parameters and ∆BMD after 6-month and 1-year treatment with RLX Neither BAP nor NTx at the baseline correlated significantly with ∆BMD at the any sites measured, either after 6-month or 1-year treatment with RLX ( Table 2,  Table 3 ). After 6-month treatment with RLX, BMD at the baseline was significantly correlated negatively with ∆BMD only at the FN (p = 0.019) ( Table 2 ). However, after 1-year treatment with RLX, BMD at the baseline was significantly correlated negatively with ∆BMD at all sites measured, including the LS, the FN, the DR (p = 0.028, 0.021, and 0.042, respectively) ( Table 3 , Fig. 1) . None of the other clinical parameters assessed at the baseline, including age, height, weight, BMI, Ca, and P at the baseline, was significantly correlated with ∆BMD at the any sites measured, either after 6-month or 1-year treatment with RLX ( Table 2, Table 3 ).
Correlation between baseline clinical parameters and ∆BTMs after 6-month and 1-year treatment with RLX BAP and NTx at the baseline were significantly correlated negatively with ∆BAP and ∆NTx both after 6-month and 1-year treatment with RLX, respectively (all p<0.001) ( Table 2, Table 3 , Fig. 2 ). BAP at the baseline was also significantly correlated negatively , and distal radius (C). ∆BMD are plotted against BMD at baseline. For each figure, the line reflects the regression, and r means the correlation coefficients. P-value for correlation between BMD at baseline and ∆BMD at each site. Fig. 2 . Correlations of bone turnover markers at baseline and ∆bone turnover markers after 1-year treatment with raloxifene. ∆BAP (A) and ∆NTx (C) are plotted against BAP and NTx at baseline, respectively. For each figure, the line reflects the regression, and r means the correlation coefficients. P-value for correlation between bone turnover markers at baseline and ∆bone turnover markers.
with ∆NTx both after 6-month and 1-year treatment with RLX, while NTx at the baseline was also significantly correlated negatively with ∆BAP after 1-year treatment with RLX ( Table 2, Table 3 ). None of the other clinical parameters assessed at the baseline, including age, height, weight, BMI, Ca, P, and BMD at any sites measured at the baseline, was significantly correlated with ∆BTMs, either after 6-month or 1-year treatment with RLX ( Table 2, Table 3 ).
Discussion
Consistent with the results of the previous studies [1, 3] , we found that RLX significantly increased BMD at the LS by 2.91 ± 7.3% at 6 months, and by 4.91 ± 6.9% at 12 months, although unexpectedly not at the FN, and that RLX significantly reduced both bone formation and resorption markers in this study. Thus, as a whole, the one-year outcome of RLX treatment in our study seemed satisfactory, compared with those observations in the previous studies [1, 3] .
In the present study, we revealed that a lower baseline value of BMD was significantly correlated with a greater increase in BMD at each site after 1-year treatment with RLX, suggesting that a lower baseline value of BMD could be a potential predictor of a greater subsequent increase in BMD on RLX treatment. In agreement with our results, Sarkar et al. [6, 7] showed the significant correlation between lower baseline BMD and greater reduction in vertebral fracture risk in RLXtreated women in the MORE cohort. In addition, in the same population, Johnell et al. [4] demonstrated that, even after multivariate analysis, lower BMD at the LS remained significant as an independent determinant of the efficacy of RLX in reducing vertebral fracture risk. Furthermore, the risk of nonvertebral fractures was also significantly decreased with RLX treatment in the subgroups of MORE patients with severe prevalent vertebral fractures (severity grade 3 in the semiquantitative method; SQ3), who had significantly lower BMD than those without prevalent vertebral fractures or with mild (SQ1) prevalent fractures [22] . On the other hand, other antiresoptive agents including bisphosphonates have also been reported to increase bone mass more in patients with lower baseline BMD [9] , consistent with our results. These results and ours suggest that RLX may be more efficacious in those patients with lower baseline BMD, as Nakamura et al. [2] have recently speculated in their review of the literature.
We also found that a higher baseline value of BAP and NTx was significantly correlated with a greater reduction in BAP and NTx, respectively, after 1-year treatment with RLX in this study. Recently, increasing evidence of a significant correlation between the reduction in BTMs and fracture risk has been reported in patients treated with RLX [5, 6] , risedronate [14] , and alendronate [15] , suggesting the reduction in BTMs as an independent predictor for the risk reduction of future fractures after treatment with antiresoptive agents. From these observations, it is tempting to speculate that our results of significant correlation between baseline values of BTMs and subsequent reductions of BTMs after RLX treatment suggest that the higher baseline values of BTMs can be used as potential predictors for the greater risk reduction of subsequent fractures on RLX treatment. In fact, based on the univariate analyses of the MORE study, Johnell et al. [4] have reported that a significantly greater vertebral fracture risk reduction was observed in patients with higher values of baseline bone turnover markers, consistent with our results. These results and ours suggest that RLX may be more efficacious in those patients with higher baseline BTMs.
A number of previous studies, using antiresorptive agents other than RLX, have repeatedly reported that higher baseline BTMs lead to greater subsequent increase in bone mass [9, 10, 12, [16] [17] [18] . However, in our study, baseline BTMs did not correlate with ∆BMD at any sites measured, either after 6-month or 1-year treatment with RLX. Considering that various antiresorptive agents act to inhibit bone resorption through different mechanisms, it may be plausible that the relationship among their effects upon BTMs, BMD, and fracture risk is quantitatively different for those agents, as Sarkar et al. [7] speculated in their report. In fact, recent data from RLX trials have demonstrated that RLX reduces the relative risk of incident vertebral fractures to a level comparable to that observed with bisphosphonates [2, 3, 23] , although RLX induces smaller increase in BMD compared with bisphosphonates [24] . Additionally, Kim et al. [13] have recently reported the difference of correlations of baseline BTMs with subsequent changes of BMD between patients treated with alendronate and those with hormone replacement therapy. Alternatively, the tendency of association, although not statistically significant, between baseline BTMs and ∆BMD found in our study may suggest that the tendency could reach significance in longer observation or larger number of subjects.
Previously, younger age used to be considered to increase the efficacy of RLX based on the results of univariate analyses of the MORE study [25] . However, from the multivariate model in the same population, younger age was no longer a significant factor in increasing its efficacy [4] . In this study, we found that younger age has a tendency to be associated with more increase in BMD at the LS after 1-year treatment with RLX, but the trend was not statistically significant, consistent with the previous studies [4] .
Since the present study has some limitations, our results should be interpreted cautiously. First, it did not include large numbers of patients. Second, we had no control subjects to compare and be more certain of the findings in this study. Third, whether our short-term results will be similarly found in a long-term study remains unclear. Finally, it is quite uncertain whether changes in BMD and BTMs after 1-year treatment are sufficient to determine final skeletal responsiveness to RTX, namely its efficacy on reducing fractures. Thus, it seems relatively difficult from our results to draw definite conclusions concerning identification of ultimate responders or nonresponders. Further studies with fracture endpoints in longer observation and larger number of patients are thus warranted to clarify whether the potentially useful predictors found in this study are of clinical relevance.
In summary, in this 12-month prospective study for the patients with postmenopausal osteoporosis treated with RLX, we found that lower baseline values of BMD at the LS, the FN, and the DR correlated significantly with greater increases of BMD at those corresponding sites, while higher baseline values of BAP and NTx correlated significantly with greater reductions of BAP and NTx, respectively. Although longer and larger studies with fracture endpoints are needed, our results suggest that baseline values of BMD and BTMs can be used to predict subsequent skeletal response to RLX therapy in Japanese women with postmenopausal osteoporosis.
